Business Standard Cipla, Kemwell form biologics JV to tap fast-growing biosimilars market
Cipla will hold 60% in the new JV with Kemwell Biopharma, aiming to develop, manufacture and commercialise biologics and biosimilars for global markets amid rising demand
Cipla will hold 60% in the new JV with Kemwell Biopharma, aiming to develop, manufacture and commercialise biologics and biosimilars for global markets amid rising demand